AAAAAA
Results: 1-25/97
Authors:
Rosen, LS
Gordon, D
Kaminski, M
Howell, A
Belch, A
Mackey, J
Apffelstaedt, J
Hussein, M
Coleman, RE
Reitsma, DJ
Seaman, JJ
Chen, BL
Ambros, Y
Citation: Ls. Rosen et al., Zoledronic acid versus pamidronate in the treatment of skeletal metastasesin patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial, CANCER J, 7(5), 2001, pp. 377-387
Authors:
Zekri, J
Ahmed, N
Coleman, RE
Hancock, BW
Citation: J. Zekri et al., The skeletal metastatic complications of renal cell carcinoma, INT J ONCOL, 19(2), 2001, pp. 379-382
Authors:
Miles, DW
Smith, IE
Coleman, RE
Calvert, AH
Lind, MJ
Citation: Dw. Miles et al., A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer, EUR J CANC, 37(11), 2001, pp. 1366-1371
Authors:
Jagdev, SP
Purohit, OP
Heatley, S
Herling, C
Coleman, RE
Citation: Sp. Jagdev et al., Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease, ANN ONCOL, 12(10), 2001, pp. 1433-1438
Authors:
Fan, M
Marks, LB
Hollis, D
Bentel, GG
Anscher, MS
Sibley, G
Coleman, RE
Jaszczak, RJ
Munley, MT
Citation: M. Fan et al., Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction?, J CL ONCOL, 19(2), 2001, pp. 543-550
Authors:
Fan, M
Marks, LB
Lind, P
Hollis, D
Woel, RT
Bentel, GG
Anscher, MS
Shafman, TD
Coleman, RE
Jaszczak, RJ
Munley, MT
Citation: M. Fan et al., Relating radiation-induced regional lung injury to changes in pulmonary function tests, INT J RAD O, 51(2), 2001, pp. 311-317
Authors:
Coleman, RE
Citation: Re. Coleman, Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases, CANC TR REV, 27(3), 2001, pp. 133-135
Authors:
Coleman, RE
Citation: Re. Coleman, Metastatic bone disease: clinical features, pathophysiology and treatment strategies, CANC TR REV, 27(3), 2001, pp. 165-176
Authors:
Ryan, JR
Dave, K
Emmerich, E
Garcia, L
Yi, L
Coleman, RE
Sattabongkot, J
Dunton, RF
Chan, AST
Wirtz, RA
Citation: Jr. Ryan et al., Dipsticks for rapid detection of Plasmodium in vectoring Anopheles mosquitoes, MED VET ENT, 15(2), 2001, pp. 225-230
Authors:
Fiorella, DJ
Provenzale, JM
Coleman, RE
Crain, BJ
Al-Sugair, A
Citation: Dj. Fiorella et al., F-18-fluorodeoxyglucose positron emission tomography and MR imaging findings in Rasmussen encephalitis, AM J NEUROR, 22(7), 2001, pp. 1291-1299
Authors:
Hoffman, JM
Coleman, RE
Citation: Jm. Hoffman et Re. Coleman, SPECT imaging in dementias - Reply, J NUCL MED, 42(7), 2001, pp. 1132-1133
Authors:
Mast, ST
Shaw, LK
Ravizzini, GC
Chambless, M
Joski, P
Coleman, RE
Borges-Neto, S
Citation: St. Mast et al., Incremental prognostic value of RNA ejection fraction measurements during pharmacologic stress testing: A comparison with clinical and perfusion variables, J NUCL MED, 42(6), 2001, pp. 871-877
Authors:
Gambhir, SS
Czernin, J
Schwimmer, J
Silverman, DHS
Coleman, RE
Phelps, ME
Citation: Ss. Gambhir et al., A tabulated summary of the FDG PET literature, J NUCL MED, 42(5), 2001, pp. 1S-93S
Authors:
Coleman, RE
Tesar, R
Phelps, M
Citation: Re. Coleman et al., HCFA and expanded coverage of PET, J NUCL MED, 42(4), 2001, pp. 11N-12N
Authors:
Lipton, A
Coleman, RE
Diel, IJ
Mundy, G
Citation: A. Lipton et al., Update on the role of bisphosphonates in metastatic breast cancer - Introduction, SEMIN ONCOL, 28(4), 2001, pp. 1-1
Authors:
Coleman, RE
Citation: Re. Coleman, Should bisphosphonates be the treatment of choice for metastatic bone disease?, SEMIN ONCOL, 28(4), 2001, pp. 35-41
Authors:
Coleman, RE
Seaman, JJ
Citation: Re. Coleman et Jj. Seaman, The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases, SEMIN ONCOL, 28(2), 2001, pp. 11-16
Authors:
Major, PP
Coleman, RE
Citation: Pp. Major et Re. Coleman, Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program, SEMIN ONCOL, 28(2), 2001, pp. 17-24
Authors:
Hagge, RJ
Wong, TZ
Coleman, RE
Citation: Rj. Hagge et al., Positron emission tomography - Brain tumors and lung cancer, RAD CLIN NA, 39(5), 2001, pp. 871
Authors:
Suwanabun, N
Sattabongkot, J
Tsuboi, T
Torii, M
Maneechai, N
Rachapaew, N
Yim-amnuaychok, N
Punkitchar, V
Coleman, RE
Citation: N. Suwanabun et al., Development of a method for the in vitro production of Plasmodium vivax ookinetes, J PARASITOL, 87(4), 2001, pp. 928-930
Authors:
Tourassi, GD
Frederick, ED
Floyd, CE
Coleman, RE
Citation: Gd. Tourassi et al., Multifractal texture analysis of perfusion lung scans as a potential diagnostic tool for acute pulmonary embolism, COMPUT BIOL, 31(1), 2001, pp. 15-25
Authors:
DeGrado, TR
Coleman, RE
Wang, SY
Baldwin, SW
Orr, MD
Robertson, CN
Polascik, TJ
Price, DT
Citation: Tr. Degrado et al., Synthesis and evaluation of F-18-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer, CANCER RES, 61(1), 2001, pp. 110-117
Authors:
Berenson, JR
Rosen, LS
Howell, A
Parter, L
Coleman, RE
Morley, W
Dreicer, R
Kuross, SA
Lipton, A
Seaman, JJ
Citation: Jr. Berenson et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases - A double-blind, randomized dose-response study, CANCER, 91(7), 2001, pp. 1191-1200
Authors:
Berenson, JR
Rosen, LS
Howell, A
Porter, L
Coleman, RE
Morley, W
Citation: Jr. Berenson et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (vol 91, pg 1191, 2001), CANCER, 91(10), 2001, pp. 1956-1956
Authors:
Jagdev, SP
Coleman, RE
Shipman, CM
Rostami-H, A
Croucher, PI
Citation: Sp. Jagdev et al., The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel, BR J CANC, 84(8), 2001, pp. 1126-1134